Enanta Pharmaceuticals (ENTA) Income towards Parent Company (2012 - 2026)

Enanta Pharmaceuticals has reported Income towards Parent Company for 15 years, with the latest figure at -$13.1 million in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company rose 42.19% year-over-year to -$13.1 million; the trailing twelve-month figure through Mar 2026 stood at -$62.0 million (up 35.58% YoY), and the FY2025 full-year result was -$81.9 million, up 29.32% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$13.1 million, down from -$11.9 million in the prior quarter.
• The five-year high for Income towards Parent Company was -$11.9 million in Q4 2025, with the low at -$39.1 million in Q2 2023.
• Historically, Income towards Parent Company has averaged -$26.4 million across 5 years, with a median of -$28.1 million in 2023.
• The largest YoY upside for Income towards Parent Company was 67.83% in 2022 against a maximum downside of 31.95% in 2022.
• Enanta Pharmaceuticals' Income towards Parent Company stood at -$29.0 million in 2022, then decreased by 15.25% to -$33.4 million in 2023, then surged by 33.28% to -$22.3 million in 2024, then surged by 46.44% to -$11.9 million in 2025, then slipped by 9.66% to -$13.1 million in 2026.
• The last three Income towards Parent Company figures came in at -$13.1 million (Q1 2026), -$11.9 million (Q4 2025), and -$18.7 million (Q3 2025), per Business Quant data.